Piramal Pharma swung to a Rs 136 crore Q3 loss as revenue fell 3%, hit by CDMO destocking, weak US biopharma funding, trade uncertainty and regulatory delays. Management sees recovery signs, cost controls cushioning EBITDA, and expects a stronger Q4.
